Second quarter revenues of $3.7 million represent a quarterly
record and a 57% increase over second quarter 2017
Recently announced FDA clearance of Deep TMS system for treatment of OCD expected to drive further revenue growth
HACKENSACK, N.J., August 27, 2018 – BrainsWay Ltd. (TASE: BRIN), a leader in the advanced non-invasive treatment of brain disorders, today announced the Company’s financial results for the three months ended June 30, 2018, and provided a corporate update.
Second Quarter 2018 Financial Highlights
Total second quarter 2018 revenue was a quarterly record $3.7 million, up 57% over the $2.4 million of total revenues in the second quarter of 2017
Recurring leasing revenues of $2.3 million, an increase of 42% over the second quarter of 2017
Sales revenues of $1.5 million in the second quarter of 2018, an increase of 85% over the second quarter of 2017
Quarterly record of newly signed contracts in the second quarter of $4.5 million increased BrainsWay’s backlog at June 30, 2018, to $29.3 million in total committed projected revenues from current leasing customers, not including additional potential usage fees
Gross margin for the second quarter of 2018 was 77%
45% reduction in operating loss to $1.0 million in the second quarter of 2018, as compared to an operating loss of $1.8 million in the second quarter of 2017
“We continue to generate significant revenue growth through the leasing and use of our Deep Transcranial Magnetic Stimulation system (Deep TMS),” said Yaacov Michlin, Chief Executive Officer of BrainsWay. “Our strong second quarter revenues of $3.7 million represented growth of 57% over the second quarter of 2017. Additionally, our backlog of committed projected revenues grew to more than $29 million at the end of the second quarter of 2018.”
“We were extremely pleased to recently receive De Novo clearance from the U.S. Food & Drug Administration (FDA) for our Deep TMS system for the treatment of obsessive-compulsive disorder (OCD) in adults. With more than two million U.S. adults suffering from OCD, this indication represents a substantial market opportunity for BrainsWay. As such, we expect the launch of Deep TMS for OCD to drive further revenue growth for the Company, and are already receiving significant interest from current and new customers in potentially adding our OCD helmet to their clinics. With FDA clearances for Deep TMS in major depressive disorder (MDD), and now OCD, BrainsWay continues to strengthen its leadership position in the non-invasive treatment of common brain disorders, and we look forward to continuing to develop our innovative technology for additional psychiatric indications,” concluded Mr. Michlin.
Corporate Highlights
Received FDA clearance for Deep TMS for treatment of OCD
First ever non-invasive medical device clearance for the treatment of OCD
Second indication granted FDA clearance for Deep TMS; MDD cleared in 2013
Received FDA clearance for next-generation stimulator, enhancing the complete Deep TMS system and streamlining treatment for physicians and their patients
Established a research collaboration with Cohen Veterans Bioscience and the Stanford University School of Medicine to identify potential biomarkers in patients suffering from Post-Traumatic Stress Disorder (PTSD)
Collaboration designed as an add-on study involving the collection and analysis of electroencephalogram data from patients currently enrolled in BrainsWay’s ongoing multi-center trial evaluating the safety and efficacy of Deep TMS for the treatment of PTSD
Continued patient recruitment into multi-center smoking cessation and PTSD clinical trials for Deep TMS; completion of recruitment in smoking cessation study expected shortly
Balance Sheet
At June 30, 2018, the Company had cash, cash equivalents and short-term deposits of $11.6 million, as compared to cash, cash equivalents and short-term deposits of $14.6 million as of December 31, 2017.
Comments